Role of Total Carnitine to Free Carnitine Ratio (TC/FC) in Monitoring Outcome of Haemodialysis
Keywords:
Total Carnitine, Free carnitine, CKD-chronic kidney disease, haemodialysisAbstract
Carnitine, a quaternary ammonium compound actively involved in beta peroxidation of fatty acids is
documented to be lost in excess in patients of chronic kidney disease (CKD) especially in those undergoing MHD,
this loss is attributable to malfunctioning of kidneys and being washed away by dialytic sessions. This decrease is
attributable to most of the complications encountered in these patients.
Objective:
To measure carnitine levels (total and free) in patients on dialysis in comparison with healthy controls
To determine total versus free carnitine ratio (TC/FC), for detecting accumulation of carnitine
metabolites.
Materials and Methods: This Observational Cross-sectional study was conducted in the department of
chemical pathology (AFIP), in collaboration with Armed forces institute of Urology (AFIU) from August 2020 to
January 2021. Non probability convenient sampling technique was employed for sampling. All individuals
undergoing dialysis for duration ≥6 months were enrolled in case cohorts. Carnitine (free and total) levels were
determined by using human bioassay ELISA kits and their ratios were calculated for comparison.
Results: 160 participants were enrolled in study subdivided as diabetic and non-diabetic groups with 1:1 male to
female ratio. TC/FC ratio was found to be high in case group, in comparison with control group. A rising trend of
ratios was observed with increasing duration of dialysis.
Conclusion: TC/FC ratio was high in dialysis patients suggestive of carnitine metabolite accumulation,
suggesting that efficacy of dialysis should be promptly monitored on the basis of TC/FC ratio for early detection
of complications secondary to carnitine metabolites accumulation
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Danya Shaukat; Zujaja Hina Haroon, Muhammad Aamir, Usama Binkhalid
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
